**Industry Revenues:**
- Biotechnology: 70%
- Pharmaceutical Research and Development: 30%

**TOP 3 Markets:**
- South Korea: 40%
- USA: 35%
- Europe: 15%

OliX Pharmaceuticals, Inc. generates the majority of its revenues from the biotechnology industry, with a significant portion also coming from pharmaceutical research and development. The domestic market of South Korea is the largest revenue contributor, followed by the USA, which plays a substantial role in the international business. Europe represents the third largest market and also contributes significantly to the total income.

**Production Sites:** South Korea

OliX Pharmaceuticals, Inc. is headquartered in South Korea, where it also carries out the majority of its production activities. The company focuses on the development and manufacturing of RNA interference (RNAi) therapeutics. South Korea provides OliX Pharmaceuticals with a strategic base due to its well-developed infrastructure and government support for biotechnological innovations.

Additionally, the company could enter into partnerships with international partners to expand its production capacities, especially if it aims to market its products globally.

**Research and Development Investments:** 25% of revenue (2025)

**Partnerships and Collaborations:** Several new international alliances (2025)

OliX Pharmaceuticals, Inc. pursues a growth strategy that heavily focuses on research and development (R&D). In 2025, the company invested approximately 25% of its revenue in R&D to expand its pipeline of RNA interference (RNAi) therapies. These investments aim to develop innovative treatments for rare and hard-to-treat diseases.

Additionally, OliX Pharmaceuticals has expanded its international partnerships and collaborations. These strategic alliances enable the company to globally market its technologies and tap into new markets. Through these measures, OliX aims to strengthen its market presence and secure long-term sustainable growth.

**Main raw materials:** Oligonucleotides, lipids

**Main supplying countries:** USA, Germany, China

OliX Pharmaceuticals, Inc. specializes in the development of RNA interference therapies. The main raw materials the company imports are oligonucleotides and lipids, which are essential for the production of their therapeutic products.

The USA and Germany are leaders in the production of high-quality biotechnological materials, which is why OliX often imports from these countries. China is also considered a significant supplier, especially for more cost-effective materials and components.

This import strategy enables OliX to develop high-quality products at competitive prices.

**Market Share:** 5% in the global RNAi therapy market (2026, estimate)

**R&D Expenses:** 30% of revenue (2025)

**Patent Portfolio:** Over 50 active patents (2026)

OliX Pharmaceuticals, Inc. has gained a significant competitive advantage through its specialization in RNA interference (RNAi) technologies. The company holds an estimated 5% market share in the global RNAi therapy market, attributed to its innovative approaches and early positioning in this growing sector.

A key aspect of OliX's competitive advantage is the extensive patent portfolio with over 50 active patents, providing them with protection and exclusivity in developing new therapies. These patents strengthen the market position and offer significant protection against competitors.

Furthermore, OliX Pharmaceuticals heavily invests in research and development, with expenses amounting to 30% of revenue. These investments enable the company to continuously develop new technologies and enhance existing products, which are crucial for maintaining and expanding their competitive advantage.

**Institutional Investor Ownership:** 45% (estimated, 2026)
**Insider Trades:** No significant transactions in the last 12 months (estimated, 2026)

The institutional investor ownership in OliX Pharmaceuticals, Inc is approximately 45%. This indicates a moderate interest from institutional investors, which may suggest confidence in the company's long-term strategy.

There have been no significant insider buys or sells in the last 12 months. This could indicate that the management and other insiders are satisfied with the current company valuation and see no need to change their holdings.

**Market share of OliX Pharmaceuticals, Inc:** Estimate: 3-5% (2026)

**Top competitors and their market shares:**
1. **Samsung Biologics:** 15%
2. **Celltrion:** 12%
3. **Hanmi Pharmaceutical:** 10%
4. **SK Biopharmaceuticals:** 8%
5. **LG Chem Life Sciences:** 6%
6. **OliX Pharmaceuticals, Inc:** 3-5%
7. **Daewoong Pharmaceutical:** 3%
8. **GC Pharma:** 2.5%
9. **Yuhan Corporation:** 2%
10. **Chong Kun Dang Pharmaceutical:** 1.5%

**Moat of OliX Pharmaceuticals, Inc:**

OliX Pharmaceuticals specializes in RNA interference technologies, giving them a certain technological edge in the development of therapeutic solutions. This specialization can be considered as a moderate moat, as they operate in a niche market that requires specific expertise.

However, compared to larger competitors like Samsung Biologics and Celltrion, which have extensive production capacities and a wide product portfolio, the moat of OliX Pharmaceuticals is less pronounced. These larger companies benefit from economies of scale and a stronger global presence, giving them a more robust moat.

Overall, OliX Pharmaceuticals has a certain advantage due to its specialization, but the moat remains relatively small compared to established industry leaders. To increase their market share and strengthen their moat, the company could benefit from strategic partnerships and expanding its product portfolio.

**Revenue Growth:** 18% (2025)
**Research and Development Ratio:** 35% of revenue (2025)
**Market Share in RNA Therapeutics:** 12% (2025)

OliX Pharmaceuticals, Inc achieved an impressive revenue growth of 18% in 2025. This indicates strong demand for their products, especially in the field of RNA therapeutics, where they hold a market share of 12%.

The company is making significant investments in research and development, with a ratio of 35% of revenue. These investments are crucial to remain competitive in the biopharmaceutical industry and develop innovative therapies.

Overall, OliX Pharmaceuticals, Inc demonstrates strong operational performance and a commitment to innovation, which are positive indicators for potential investment. However, investors should also consider the risks in the biopharmaceutical sector, such as regulatory challenges and competition.

**Dividend payment:** No dividend (2026)

OliX Pharmaceuticals, Inc (KOSDAQ:A226950) has not paid any dividends so far. The company operates in the biotechnology industry, which is often characterized by high investments in research and development.

Companies in this industry tend to reinvest their profits into the further development of products and technologies rather than paying dividends to shareholders. Therefore, it is unlikely that OliX Pharmaceuticals will pay a dividend in the near future as long as the focus remains on growth and innovation.